- ARYL SUBSTITUTED HETEROCYCLYL SULFONES
-
The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
- -
-
Page/Page column 76
(2015/11/09)
-
- SUBSTITUTED CYCLOPROPYL COMPOUNDS
-
Substituted cyclopropyl piperidinyl compounds and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-1 19. Pharmaceutical compositions and methods of treatment are also included.
- -
-
Page/Page column 51
(2014/04/17)
-
- SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME
-
The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof and a pharmaceutical composition for treating metabolism-related disorder containing the same. Specifically, the present invention relates to a compound of the formula 1, which can activate GPR119 to treat metabolism-related disorders, including diabetes and related diseases, diabetes-related microvascular complications, diabetes-related macrovascular complications, cardiovascular abnormalities, metabolic syndrome and its constituent diseases, and obesity.
- -
-
Paragraph 102; 103; 104; 105; 106
(2013/07/25)
-
- GPR119 Receptor Agonists
-
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
- -
-
Page/Page column 19
(2009/12/05)
-
- Phenyl heterocyclyl ethers
-
The invention relates to compounds of formula I
- -
-
-